AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

The trial will assess ENHERTU (at a dose of 5.4 mg/kg) in combination with either rilvegostomig or pembrolizumab, compared to the current standard of care, platinum-based chemotherapy (carboplatin ...

For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of ...

Seagate Technology Holdings (NASDAQ:STX) provides data storage technology and infrastructure solutions internationally. It ...

I rebuilt my life after breast cancer—finding love, moving states, and embracing joy. Then, everything turned upside down.

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking.

Zongertinib met its primary objective, with an objective response rate of 66.7% and a low rate (3%) of treatment discontinuations due to toxicity in the NSCLC group given the dose selected for the ...

A so-called antibody-drug conjugate, Enhertu combines the active agent in Herceptin with a chemotherapy toxin, delivering a more potent drug dose directly to HER2-expressing tumor cells than can be ...